Meir Rinde


Fixed-Duration Therapy Struggles to Find Footing Across Tumor Types

March 28th 2022

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

Oncology Care Evolves as Lasting COVID-19 Effects Come Into Focus

March 9th 2022

The pandemic appears to have caused or contributed to a number of lasting changes in the way oncologists provide clinical care to their patients.

Home Infusion Trend Stirs Debate

November 24th 2021

The COVID-19 pandemic spurred the launching or expansion of in-home cancer therapy infusion programs at several oncology centers around the United States, drawing a surge of interest throughout the field as well as opposition from oncologists who are concerned about the implications for patient safety and the potential impact on community practices that provide in-house infusion services.

Lung Cancer Pioneer Paves Path for Future Innovation

September 24th 2021

The achievements of Roman Perez-Soler, MD, include studies of anti-EGFR therapies and topoisomerase inhibitors, extensive research on liposomal delivery systems, and early work on patient-derived xenografts in mice.

Cardio-oncology Specialists Pave Optimal Treatment Path for Patients With Cancer

August 4th 2021

The subspecialty of cardio-oncology has grown in recent years as improved cancer survival rates have expanded the population of long-term survivors with heightened risk of cardiovascular disease and drawn more attention to the need for preventive strategies and disease management.

Emerging Therapies Expand Options in Lung Cancer

July 23rd 2021

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and EGFR exon 20 mutations as well as continued progress in developing new therapies for subsets of patients with other molecularly targetable alterations and with PD-L1–high disease.

Moving Curative Therapies Forward in Hematologic Malignancies

June 17th 2021

Because hematological cancers are rarer than solid tumors, information on treatment practices is somewhat less available, so hematologists are particularly interested in learning what their peers are doing.

COVID-19 Jumpstarts RNA Cancer Vaccine Field

April 8th 2021

The success of the COVID-19 vaccines based on messenger RNA has led to a surge of interest from investigators, pharmaceutical companies, and investors in similar technology for other diseases, including a number of oncology indications.

COVID-19 Spurs New Therapy Trends

March 12th 2021

When the coronavirus disease 2019 pandemic started upending health care services throughout the United States a year ago, the oncology community moved quickly to develop guidance on selecting therapies and setting treatment schedules for many cancers to allow for less frequent in-patient visits to clinics and infusion centers.

Surge of New Drugs Fuels Optimism in Pediatric Oncology

February 4th 2021

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

COVID-19 Sharpens Focus on Drug Holidays

December 3rd 2020

Having patients go on drug holidays or intermittent therapy is a common strategy during treatment of prostate cancer and several other malignancies, whether to provide temporary relief from adverse effects influencing quality of life, to prevent long-term health impacts, or to lessen drug resistance that would render the therapy ineffective.

CAR T-Cell Research Surges

November 16th 2020

Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.

First CRISPR Cancer Results Fuel Hope

March 30th 2020

Results from the first FDA-approved in-human trial of CRISPR-edited T cells for cancer treatment suggest that such therapies can be used safely in patients, allaying some of the concerns about potential AEs and advancing progress toward the development of more effective cell-based immunotherapies.

Breathing New Life Into Chemotherapy

March 2nd 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

BRCA Rules Leave Patients Behind

November 1st 2019

Updated guidelines from the United States Preventive Services Task Force on BRCA1/2 genetic testing recommend risk assessment, counseling, and genetic test-ing for women who meet certain criteria but fall short of encompassing important groups of individuals who are at risk for developing BRCA1/2 mutation–driven disease

New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma

October 4th 2019

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Broader NGS Use in Oncology Hinges on Payers, Access, and Education

August 16th 2019

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Primary Cancer Mysteries Persist Even in the Genomic Era

July 1st 2019

Although diagnostic techniques have improved over the past several decades, cancers of unknown primary origin are a lingering feature of clinical practice, frustrating attempts to develop new protocols through molecularly driven strategies.

Experts Say DCIS Requires Focus on Genomics and Microenvironment

May 21st 2019

Identifying patients with DCIS who are more likely to develop invasive breast cancer remains a challenge. However, two major areas of study are the appropriate use of active surveillance and the use of biomarkers observed in the DCIS microenvironment to determine risk.